GTX-11 improves portal hypertension, liver fibrosis, and sinusoidal cells phenotype in experimental MASH

Background & Aims: Steatotic liver disease can lead to the development of metabolic dysfunction-associated steatohepatitis (MASH), the prevalence of which is rapidly increasing, intensifying the need to find an effective treatment. GTX-11 is a first-in-class drug with anti-inflammatory and antif...

Descripció completa

Dades bibliogràfiques

Autors principals:	María Andrés-Rozas, Zoe Boyer-Diaz, Eugènia Ruiz-Cánovas, Peio Aristu-Zabalza, Sergi Guixé-Muntet, Cristina Fernández-Asensio, Juan José Lozano, Noemí García-Delgado, Carla Fuster, Jaume Mercade, Jaime Bosch, Jordi Gracia-Sancho
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2025-10-01
Col·lecció:	JHEP Reports
Matèries:	Liver cirrhosis Portal hypertension HSC LSEC MASLD
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2589555925001752
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!